127 related articles for article (PubMed ID: 15076143)
21. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma.
Phan GQ; Attia P; Steinberg SM; White DE; Rosenberg SA
J Clin Oncol; 2001 Aug; 19(15):3477-82. PubMed ID: 11481353
[TBL] [Abstract][Full Text] [Related]
22. High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinoma.
Abrams JS; Rayner AA; Wiernik PH; Parkinson DR; Eisenberger M; Aronson FR; Gucalp R; Atkins MB; Hawkins MJ
J Natl Cancer Inst; 1990 Jul; 82(14):1202-6. PubMed ID: 2194036
[TBL] [Abstract][Full Text] [Related]
23. Interleukin-2: clinical applications.
Atkins MB
Semin Oncol; 2002 Jun; 29(3 Suppl 7):12-7. PubMed ID: 12068383
[TBL] [Abstract][Full Text] [Related]
24. Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma.
White RL; Schwartzentruber DJ; Guleria A; MacFarlane MP; White DE; Tucker E; Rosenberg SA
Cancer; 1994 Dec; 74(12):3212-22. PubMed ID: 7982185
[TBL] [Abstract][Full Text] [Related]
25. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
26. Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2.
Quan WD; Walker PR; Quan FM; Ramirez M; Elsamaloty HM; Ghai V; Vinogradov M; Liles DK
Cancer Biother Radiopharm; 2006 Oct; 21(5):437-42. PubMed ID: 17105418
[TBL] [Abstract][Full Text] [Related]
27. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.
Rosenberg SA; Lotze MT; Yang JC; Topalian SL; Chang AE; Schwartzentruber DJ; Aebersold P; Leitman S; Linehan WM; Seipp CA
J Natl Cancer Inst; 1993 Apr; 85(8):622-32. PubMed ID: 8468720
[TBL] [Abstract][Full Text] [Related]
28. Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma.
Smith II JW; Kurt RA; Baher AG; Denman S; Justice L; Doran T; Gilbert M; Alvord WG; Urba WJ
J Immunother; 2003; 26(2):130-8. PubMed ID: 12616104
[TBL] [Abstract][Full Text] [Related]
29. [Hyperdynamic hemodynamics following high-dose interleukin 2-interferon alpha therapy in patients with metastatic renal cell carcinoma. Immunotherapy as a clinical sepsis model?].
Finck-Seelen ; Lampert R; Brandt L
Anaesthesist; 1996 Dec; 45(12):1171-8. PubMed ID: 9065251
[TBL] [Abstract][Full Text] [Related]
30. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer.
Kammula US; White DE; Rosenberg SA
Cancer; 1998 Aug; 83(4):797-805. PubMed ID: 9708948
[TBL] [Abstract][Full Text] [Related]
31. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma.
Wigginton JM; Komschlies KL; Back TC; Franco JL; Brunda MJ; Wiltrout RH
J Natl Cancer Inst; 1996 Jan; 88(1):38-43. PubMed ID: 8847724
[TBL] [Abstract][Full Text] [Related]
32. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
33. High-Dose Interleukin-2: Evaluation of a Standardized Order Set for Biotherapy in an Intensive Care Unit
.
Portillas R; Turner B; Jeffers A; Chen LL; Champagne M
Clin J Oncol Nurs; 2017 Apr; 21(2):E49-E53. PubMed ID: 28315535
[TBL] [Abstract][Full Text] [Related]
34. Gastrointestinal perforation in light chain amyloidosis in the era of novel agent therapy - a case series and review of the literature.
Shaulov A; Avivi I; Cohen Y; Duek A; Leiba M; Gatt ME
Amyloid; 2018 Mar; 25(1):11-17. PubMed ID: 29241368
[TBL] [Abstract][Full Text] [Related]
35. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.
Gollob JA; Veenstra KG; Parker RA; Mier JW; McDermott DF; Clancy D; Tutin L; Koon H; Atkins MB
J Clin Oncol; 2003 Jul; 21(13):2564-73. PubMed ID: 12829677
[TBL] [Abstract][Full Text] [Related]
36. Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma.
Eton O; Rosenblum MG; Legha SS; Zhang W; Jo East M; Bedikian A; Papadopoulos N; Buzaid A; Benjamin RS
Cancer; 2002 Jul; 95(1):127-34. PubMed ID: 12115326
[TBL] [Abstract][Full Text] [Related]
37. A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects.
Vlasveld LT; Rankin EM; Hekman A; Rodenhuis S; Beijnen JH; Hilton AM; Dubbelman AC; Vyth-Dreese FA; Melief CJ
Br J Cancer; 1992 May; 65(5):744-50. PubMed ID: 1586602
[TBL] [Abstract][Full Text] [Related]
38. Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma.
Diaz JP; Tew WP; Zivanovic O; Konner J; Sabbatini PJ; dos Santos LA; Abu-Rustum NR; Chi DS; Aghajanian C; Barakat RR
Gynecol Oncol; 2010 Mar; 116(3):335-9. PubMed ID: 20004956
[TBL] [Abstract][Full Text] [Related]
39. A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma.
Mittelman A; Huberman M; Puccio C; Fallon B; Tessitore J; Savona S; Eyre R; Gafney E; Wick M; Skelos A
Cancer; 1990 Aug; 66(4):664-9. PubMed ID: 2386896
[TBL] [Abstract][Full Text] [Related]
40. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells.
Bar MH; Sznol M; Atkins MB; Ciobanu N; Micetich KC; Boldt DH; Margolin KA; Aronson FR; Rayner AA; Hawkins MJ
J Clin Oncol; 1990 Jul; 8(7):1138-47. PubMed ID: 2358835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]